Abstracts tagged "Biologicals"

Abstract Number: 1135 • ACR Convergence 2024
Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Richard Warren¹, April W. Armstrong², Shinichi Imafuku³, Akimichi Morita⁴, Carle Paul⁵, Matthias Augustin⁶, Thierry Passeron⁷, Leon Kircik⁸, Eleni Vritzali⁸, Thomas Scharnitz⁹, Georgene Schroeder⁹, Subhashis Banerjee¹⁰ and Bruce Strober¹¹, ¹Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²University of California Los Angeles, Los Angeles, ³Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, ⁴Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵Toulouse University and CHU, Toulouse, France, ⁶Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁷Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Bristol Myers Squibb, Princeton, ¹⁰Bristol Myers Squibb, Princeton, NJ, ¹¹Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 1460 • ACR Convergence 2024
Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Lou Kawka¹, Jacques-Eric Gottenberg², Jérôme Avouac³, OLIVIER BROCQ⁴, GILLES HAYEM⁵, Xavier Mariette⁶, Alain Meyer⁷, BENOIT FLACHAIRE⁸, OLIVIER FOGEL⁹, ARTHUR GANDIOLLE¹⁰, MANON LESTURGIE¹¹, JEAN-FRANCOIS KLEINMANN¹², Samira Ahmed Yahia¹³ and Thao Pham¹⁴, ¹Hôpital Universitaire de Strasbourg, Strasbourg, Alsace, France, ²Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁵Groupe Hospitalier Paris Saint-Joseph, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁷UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁸Aix Marseille University, Marseille, France, ⁹AP-HP, Paris, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Cochin hospital, Paris, France, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Hôpital Universitaire de Strasbourg, Strasbourg, France, ¹⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: This study aimed to evaluate the clinical scenarios in which clinicians initiate cTT, as well as the safety and effectiveness of cTT in patients…
Abstract Number: 1554 • ACR Convergence 2024
Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials
Karen Costenbader¹, Joan Merrill², Marta Mosca³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald van Vollenhoven⁹, ¹Brigham and Women’s Hospital, Division of Rheumatology, Inflammation and Immunity, Harvard Medical School, Boston, MA, ²Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Program, Oklahoma City, OK, ³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands

Background/Purpose: There are benefits of early treatment for autoimmune diseases; however, data are not available for patients (pts) with SLE as there is no definition…
Abstract Number: 2012 • ACR Convergence 2024
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
Orrin Troum¹, John Botson², Fang Fang³, Katie Obermeyer³, Supra Verma³ and Brian LaMoreaux⁴, ¹Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, ²Orthopedic Physicians Alaska, Anchorage, AK, ³Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase, infused every 2 weeks over ≥2 hrs, lowers serum urate (SU) in patients with refractory gout. Decreasing infusion time is expected to improve…
Abstract Number: 2281 • ACR Convergence 2024
Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
Monica Luque¹, Kristina Zhelyazkova¹, Laxmikant Vashishta², Masna Rai³, Abid Sattar⁴, Richard Bucknall⁴, Steffen Leutz³ and FAUSTO BERTI¹, ¹Alvotech, Zürich, Switzerland, ²Alvotech, Bangalore, India, ³Alvotech, Jülich, Germany, ⁴Alvotech, London, United Kingdom
Background/Purpose: Golimumab is a safe and effective treatment for RA. Biosimilars to the reference product (RP) may make treatment more accessible. We assessed comparable efficacy…
Abstract Number: 2515 • ACR Convergence 2024
Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study
Weiyi Xia¹, Jiachen Li¹, Tian Liu¹ and Yuhui Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University, BeiJing, China
Background/Purpose: The aim of this prospective cohort study is to evaluate the efficacy and safety of Janus kinase (JAK) inhibitor upadacitinib in refractory Behçet’s Syndrome…
Abstract Number: 0019 • ACR Convergence 2024
A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Theresa Hunter¹, Ferran Soldevila¹, Yan Zhang¹, Brittany Ross¹, Daiki Matsuda¹, Yanjie Bao¹, John Li¹, Michelle Nguyen¹, Matthew Butcher¹, MIchael Pica¹, Claudia Fernandez¹, James Vestal¹, Goutam Mondal¹, Yi Kuo¹, Jeffrey Chen¹, Josephine Nguyen², Young Yoon Choi², Diana Galvan¹, Duy Nguyen¹, Donald Jhung², Stuart Sievers¹, Steven Tanis¹, Cory Bentley², Michael Rosenzweig¹, Priya Karmali¹, Adrian Bot¹, Haig Aghajanian¹ and Gregor Adams¹, ¹Capstan Therapeutics, San Diego, CA, ²Capstan Therapeutics, San Diego
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating clinical efficacy in various autoimmune disease indications. Despite…
Abstract Number: 0400 • ACR Convergence 2024
Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children
Jacqueline Bui¹, Jacob Curry², Jessica Kent³, Payton Danosky⁴, Kellen Sanders⁴, Sriya Paluvayi⁴, Wendy Garcia⁴, Alejandra Ruppe⁴, Megan Cheung⁴, Anna Saack⁴, Xinrui Bao⁴, Audrey Luey⁴, Michelle Kim⁴, Emily McDaniel⁴, Amanda Chiu⁴, Sophia Ahn⁵, Ji-Won Park⁴, Sudheshna Thirunahari⁴, Cammie Wei⁴, Liau Adriel⁵, Sophia Pham⁴, Sadie Van Den Bogaerde⁴, Joshua Scheck⁴, Ian Muse⁶, Ava Klein⁵, Xing Wang⁷, James Cassat⁸ and Yongdong Zhao⁶, ¹Seattle Children’s Research Institute, University of Washington, Bellevue, WA, ²Seattle Children’s Research Institute, Vanderbilt University Medical Center, Seattle, WA, ³Seattle Children’s Research Institute, Medical College of Wisconsin, Seattle, WA, ⁴Seattle Children’s Research Institute, University of Washington, Seattle, WA, ⁵Seattle Children’s Research Institute, University of Washington, Seattle, ⁶Seattle Children's Research institute, Seattle, WA, ⁷Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ⁸Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease in which osteoclastogenesis may play a critical role. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was shown…
Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0606 • ACR Convergence 2024
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
Bonit Gill¹, Jack Geiger¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk ofmajor adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardialinfarction (MI),…
Abstract Number: 0870 • ACR Convergence 2024
The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use
George Karpouzas¹, Elena Myasoedova², Miguel Angel Gonzalez-Gay³, alfonso Corrales-Martínez⁴, Solbritt Rantapaa-Dahlqvist⁵, Petros Sfikakis⁶, Patrick Dessein⁷, Linda Tsang⁸, Carol Hitchon⁹, Hani El Gabalawy¹⁰, Virginia Pascual Ramos¹¹, Irazu Contreras Yanez¹², Iris Jazmín Colunga Pedraza¹³, Dionicio Galarza-Delgado¹⁴, jose Ramon Azpiri-Lopez¹⁵, Anne Grete Semb¹⁶, Piet Van RIel¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and An inTernationAl Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA), ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, ²Mayo Clinic, Rochester, MN, ³University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Umeå University, Umeå, Sweden, ⁶Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁷University of Witwatersrand, Johannesburg, South Africa, ⁸University of Witwatersrand, Johanessburg, South Africa, ⁹University of Mannitoba, Winnipeg, Canada, ¹⁰University of Mannitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹²Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁶Diakonhjemmet Hospital, Oslo, Norway, ¹⁷Radboud University Medical Center, Nijmegen, Netherlands, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: The impact of body mass index (BMI) as a surrogate of body fat content on cardiovascular (CV) risk in rheumatoid arthritis (RA) is unclear.…
Abstract Number: 1162 • ACR Convergence 2024
Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom
Xia Lyu¹, Patrick Gordon², Harsha Gunawardena³, Neil McHugh⁴, Sarah Tansley⁴, Athiveeraramapandian Prabu⁵, Peter Lanyon⁶, James Miller⁷, Voon Ong⁸, Anthony Isaacs⁹, Chee-Seng Yee¹⁰, Caroline Cotton¹¹, Patrick Kiely¹², Eleni Stathopoulou¹³, James Taylor¹⁴, Rachel Jeffery¹⁴, Anurag Bharadwaj¹⁵, James Lilleker¹⁶, Janine Lamb¹⁷ and hector Chinoy¹⁸, and MYOPROSP consortium, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ²nhs, London, United Kingdom, ³North Bristol NHS Trust, and Academic Rheumatology, University of Bristol, Bath, United Kingdom, ⁴University of Bath, Bath, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁶Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom, ⁷Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁸University College London, London, England, United Kingdom, ⁹Department of Rheumatology, London North West University Healthcare NHS Trust, London, United Kingdom, ¹⁰Department of Rheumatology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ¹¹Department of Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom, ¹²Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom, ¹³Department of Rheumatology, Solihull Hospital, University Hospitals of Birmingham NHS FT, Birmingham, United Kingdom, ¹⁴Department of Rheumatology, Northampton General Hospital, Northampton General Hospital NHS Trust, Northampton, United Kingdom, ¹⁵1Basildon University Hospital, Mid & South Essex NHS Foundation Trust, Rheumatology, Basildon, United Kingdom, Basildon, United Kingdom, ¹⁶Northern Care Alliance NHS Trust, Salford, United Kingdom, ¹⁷University of Manchester, UK, Manchester, United Kingdom, ¹⁸The University of Manchester, Manchester, United Kingdom
Background/Purpose: B cell depletion in the form of rituximab (RTX) is an established treatment modality for idiopathic inflammatory myopathies (IIM). Treatment response is now assessed…
Abstract Number: 1464 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, Mitsumasa Kishimoto⁴, Ennio Lubrano⁵, Proton Rahman⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Minni Koivunen⁹, Frederic Lavie¹⁰, Enrique R. Soriano¹¹, Ruben Queiro Silva¹², Frank Behrens¹³ and Stefan Siebert¹⁴, ¹Sorbonne Université, Paris, France, ²Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁵Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁶Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Data Sciences Staffing Solutions, IQVIA, Inc, Budapest, Hungary, ⁹Janssen Cilag Oy, Espoo, Finland, Espoo, Finland, ¹⁰Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, ¹³University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ¹⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Many drugs are available in PsA and have demonstrated efficacy in randomized controlled trials (RCTs); however, real-world long-term data of drugs are scarce. PsABIOnd…
Abstract Number: 1595 • ACR Convergence 2024
Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Margot Poux¹, Matthieu Groh², Alexandra Nanzerkelly³, Marco Caminati⁴, candice Lacroix⁵, stephanie Habib⁶ and Benjamin Terrier⁷, ¹Université de Paris cité, PARIS 04EME, France, ²Foch, Suresnes, France, ³King's college London, London, ⁴Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ⁵Université de Paris cité, Paris, ⁶Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis associated with asthma and blood and tissue eosinophilia. EGPA is often associated with glucocorticoid…
Abstract Number: 2028 • ACR Convergence 2024
Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment
Marta López I Gómez¹, Paula García Escudero², Berta Magallanes López³, Alicia García Dorta⁴, Beatriz Frade-Sosa⁵, Meritxell Sallés Lizarzaburu⁶, Íñigo Rúa-Figueroa⁷, Dolly Viviana Fiallo Suárez⁸, Francisco Javier Toyos Sáenz de Miera⁹, Rafael Benito Melero-Gonzalez¹⁰, Diego Dios Santos¹¹, Jose Alberto Miranda¹², Clara Garcia Belando¹³, Giuliano Boselli¹⁴, Alina Lucica Boteanu¹⁵, Cristina Corrales Selaya¹⁶, cristiana sieiro santos¹⁷, Elvira Díez Álvarez¹⁸, Judit Font¹⁹, Elena Riera Alonso²⁰, Ernesto Trallero Araguás²¹, Eugenia Enríquez Merayo²², Maria Rodriguez-Laguna²³, irene monjo²⁴, Ignacio Vázquez Gómez²⁵, Paloma Vela-Casasempere²⁶, Carolina Merino²⁷, Marta Ibáñez Martínez²⁸, José Ángel Hernández Beriain²⁹, ALBERTO MARIANO RUIZ ROMAN³⁰ and Jaime Calvo-Alén³¹, ¹Hospital Universitario Alava, Vitoria, Pais Vasco, Spain, ²Hospital Universitario Araba, Vitoria, ³Hospital de la Santa Creu i Sant Pau, Barcelona, ⁴Rheumatologist, La Laguna, Spain, ⁵Hospital Clinic de Barcelona, Barcelona, Spain, ⁶Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ⁷Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁸H. U. de Gran Canaria. Dr. Negrin, H. U. de Gran Canaria, ⁹H. U. Virgen Macarena, H. U. Virgen Macarena, ¹⁰CHU Ourense, O Carballino, Spain, ¹¹C. H. U. A Coruña, C. H. U. A Coruña, ¹²C. H. U. Lucus Augusti (Lugo), (Lugo), ¹³H. C. U. Virgen de la Arrixaca, Murcia, ¹⁴hospital miguel servet, zaragoza, Aragon, Spain, ¹⁵H.U. Ramón y Cajal, Madrid, Spain, ¹⁶Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ¹⁷Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ¹⁸Complejo Asistencial Universitario de León, León, Spain, ¹⁹Hospital Germans Trias i Pujol, Barcelona, Spain, ²⁰Mutua de Terrasa, Barcelona, ²¹Hospital Vall D'Hebron, Barcelona, Spain, ²²Hospital 12 de Octubre, Madrid, ²³Resident in Rheumatology, Madrid, Spain, ²⁴University Hospital La Paz, Madrid, Spain, ²⁵H. U. Dr. Peset, Valencia, ²⁶Hospital General Universitario Alicante, Alicante, Spain, ²⁷Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²⁹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain, ³⁰Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, ³¹Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain
Background/Purpose: Nearly four years since its characterization, management and therapeutic algorithms for VEXAS syndrome remain unclear. This study aims to describe treatment approaches and assess…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].